Design and development of orally disintegrating films: A platform based on hydroxypropyl methylcellulose and guar gum

From a design of experiments (DOE) performed under four independent variables, with the filmogenicity conditions and shortest disintegration time as the answers, a new oral disintegrating film (ODF) based on hydroxypropyl methylcellulose (HPMC) and guar gum (GG) with the essential oil of Plectranthu...

Full description

Saved in:
Bibliographic Details
Published in:Carbohydrate polymers 2023-01, Vol.299, p.120155-120155, Article 120155
Main Authors: Carvalho, Ana Flávia Freitas de, Caldeira, Vanessa Ferreira, Oliveira, Ana Paula, Gonsalves, Joyce Kelly Marinheiro da Cunha, Araújo, Edigênia Cavalcante da Cruz
Format: Article
Language:English
Subjects:
Candida
Carvacrol
Essential oil
Galactans
Hypromellose Derivatives
Mannans
Plectranthus amboinicus L
Quantitative nuclear magnetic resonance
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:From a design of experiments (DOE) performed under four independent variables, with the filmogenicity conditions and shortest disintegration time as the answers, a new oral disintegrating film (ODF) based on hydroxypropyl methylcellulose (HPMC) and guar gum (GG) with the essential oil of Plectranthus amboinicus L. (EOPA) was developed. Sixteen formulations were tested for filmogenicity, homogeneity, and viability. The better selected ODF required 230.1 s for complete disintegration. The retention rate of the EOPA was quantified using the nuclear magnetic resonance hydrogen technique (H1 NMR), which identified the presence of 0.14 % carvacrol. The scanning electron microscopy showed a smooth and homogeneous surface with the presence of small white dots. Through the disk diffusion test, the EOPA was able to inhibit the growth of clinical strains of the Candida genus and gram-positive and gram-negative bacterial strains. This work opens new perspectives for the development of antimicrobial ODFS used in clinical practice. [Display omitted]
ISSN:0144-8617
1879-1344
DOI:10.1016/j.carbpol.2022.120155